Latest Morpholines Stories
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
- Final results from binimetinib Phase 2 in NRAS melanoma confirmed prior Progression Free Survival result and demonstrated encouraging Overall Survival- BOULDER, Colo., Nov.
The Firm is evaluating Xarelto lawsuits on behalf of individuals who experienced uncontrollable bleeding and other serious complications, allegedly due to their use of the blood thinner.
Defendant Xarelto manufacturers want several lawsuits dismissed from Pennsylvania state court, arguing that there is no connection with the state. Rockville
The results of a recently-concluded study purport to show that Xarelto (rivaroxaban) is as safe as warfarin for patients atrial fibrillation patients awaiting elective cardioversion, even though
X-VeRT Study Results Presented as a Hot Line Session at the ESC Congress 2014 and Published in European Heart Journal BARCELONA, Spain, Sept.
SAN DIEGO, Aug.
-- Results from X-VeRT, the first prospective exploratory study of a Factor Xa inhibitor in patients with atrial fibrillation undergoing cardioversion, will be presented during an ESC Congress 2014
The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news.
Array planning for potential return of MEK inhibitor BOULDER, Colo., Aug. 12, 2014 /PRNewswire/ -- Array BioPharma Inc.
- A small wooded valley; a dell.
- The protecting weather-shed built around the entrance to a house.
- The roofed-over space between the kitchen and the sleeping-quarters in a logging-camp, commonly used as a storeroom.